268 related articles for article (PubMed ID: 17975550)
21. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
22. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
Davies SW; Turmaine M; Cozens BA; DiFiglia M; Sharp AH; Ross CA; Scherzinger E; Wanker EE; Mangiarini L; Bates GP
Cell; 1997 Aug; 90(3):537-48. PubMed ID: 9267033
[TBL] [Abstract][Full Text] [Related]
23. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
24. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
Graham RK; Slow EJ; Deng Y; Bissada N; Lu G; Pearson J; Shehadeh J; Leavitt BR; Raymond LA; Hayden MR
Neurobiol Dis; 2006 Feb; 21(2):444-55. PubMed ID: 16230019
[TBL] [Abstract][Full Text] [Related]
25. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
[TBL] [Abstract][Full Text] [Related]
26. Huntington's disease: from pathology and genetics to potential therapies.
Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
[TBL] [Abstract][Full Text] [Related]
27. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease.
Li SH; Yu ZX; Li CL; Nguyen HP; Zhou YX; Deng C; Li XJ
J Neurosci; 2003 Jul; 23(17):6956-64. PubMed ID: 12890790
[TBL] [Abstract][Full Text] [Related]
28. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
29. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
30. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction.
Goswami A; Dikshit P; Mishra A; Mulherkar S; Nukina N; Jana NR
Biochem Biophys Res Commun; 2006 Mar; 342(1):184-90. PubMed ID: 16472774
[TBL] [Abstract][Full Text] [Related]
31. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
Chang R; Liu X; Li S; Li XJ
Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
[TBL] [Abstract][Full Text] [Related]
32. Characterization of neuron-specific huntingtin aggregates in human huntingtin knock-in mice.
Sawada H; Ishiguro H; Nishii K; Yamada K; Tsuchida K; Takahashi H; Goto J; Kanazawa I; Nagatsu T
Neurosci Res; 2007 Apr; 57(4):559-73. PubMed ID: 17335925
[TBL] [Abstract][Full Text] [Related]
33. Arfaptin 2 regulates the aggregation of mutant huntingtin protein.
Peters PJ; Ning K; Palacios F; Boshans RL; Kazantsev A; Thompson LM; Woodman B; Bates GP; D'Souza-Schorey C
Nat Cell Biol; 2002 Mar; 4(3):240-5. PubMed ID: 11854752
[TBL] [Abstract][Full Text] [Related]
34. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
35. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
36. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
Gil-Mohapel JM
CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain.
Dorsman JC; Smoor MA; Maat-Schieman ML; Bout M; Siesling S; van Duinen SG; Verschuuren JJ; den Dunnen JT; Roos RA; van Ommen GJ
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1061-7. PubMed ID: 10434306
[TBL] [Abstract][Full Text] [Related]
38. Dysfunction of the ubiquitin ligase Ube3a may be associated with synaptic pathophysiology in a mouse model of Huntington disease.
Maheshwari M; Samanta A; Godavarthi SK; Mukherjee R; Jana NR
J Biol Chem; 2012 Aug; 287(35):29949-57. PubMed ID: 22787151
[TBL] [Abstract][Full Text] [Related]
39. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
Mangiarini L; Sathasivam K; Seller M; Cozens B; Harper A; Hetherington C; Lawton M; Trottier Y; Lehrach H; Davies SW; Bates GP
Cell; 1996 Nov; 87(3):493-506. PubMed ID: 8898202
[TBL] [Abstract][Full Text] [Related]
40. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Nguyen T; Hamby A; Massa SM
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
